Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

MaxCyte (MXCT)

Price 295.00p on 26-04-2024 at 16:30:01
Change 0.00p 0%
Buy 300.00p
Sell 290.00p
Buy / Sell MXCT Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 5,000.00 at 290.00p
Day's Volume: 5,668
Last Close: 295.00p
Open: 295.00p
ISIN: US57777K1060
Day's Range 295.00p - 295.00p
52wk Range: 172.50p - 420.00p
Market Capitalisation: £307m
VWAP: 291.13691p
Shares in Issue: 104m

Listed In: FTSE AIM 100, FTSE AIM All-Share,

Recent Trades History MaxCyte (MXCT)
Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 5,000 290.00p Ordinary
 15:20:27 - 26-Apr-24
Buy* 550 300.00p Ordinary
 13:30:59 - 26-Apr-24
Buy* 118 298.00p Ordinary
 10:05:38 - 26-Apr-24

Share Price History for MaxCyte
Time period:
to
Date Open High Low Close Volume

Share News for MaxCyte

TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout

2nd Apr 2024 15:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%

13th Mar 2024 11:54

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Net loss widens to USD37.9 million in 2023 from USD23.6 million in 2022, as revenue declines by 6.7% to USD41.3 million from 44.3 million. Core business revenue falls by 25% to USD29.8 million from USD39.6 million, but strategic platform license programme-related revenue more than doubles to USD11.5 million from USD4.6 million. In the fourth quarter alone, revenue is USD15.7 million, up 26% from USD12.4 million a year before, as core business revenue falls by 32% but SPL revenue more than quadruples. Read More

EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit

5th Mar 2024 20:43

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

5th Mar 2024 16:06

Read More

IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen

30th Jan 2024 13:58

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Signs strategic platform licence with Wugen Inc, a US-based clinical-stage biotech company developing off-the-shelf cell therapies for the treatment of hematological and solid cancer tumour malignancies. Wugen's lead program is evaluating WU-CART-007, a cell therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia. Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's unique Flow electroporation technology and its trademarked ExPERT research platform. In exchange, MaxCyte will receive annual licence fees and programme-related revenue, although precise transaction details were not provided. Read More

FTSE 100 Latest
Value8,139.83
Change60.97

Login to your account

Forgot Password?

Not Registered